Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
← catalyst calendarNCT06975787 · readout in 1,118 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
90estimated
Sites
18
Countries
France, Germany, South Korea +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-22 | actual | When the study began enrolling |
| Primary completion | 2029-09-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-09-10 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lupus Nephritis (LN)
Interventions
- Drug: Vonsetamig — also filed as REGN5459
- Drug: Odronextamab — also filed as REGN1979
Primary outcomes
what the primary-completion date above is the date OFOccurrence of Dose Limiting Toxicities (DLT)
measured Up to 56 days
Occurrence of Treatment Emergent Adverse Events (TEAEs)
measured Through week 76
Severity of TEAEs
measured Through week 76
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed